Takeda Announces Strategic Leadership Changes to Help Drive Continued Growth and Competitiveness in Global Marketplace

OSAKA, Japan and CAMBRIDGE, Massachusetts, February 3, 2022 – Takeda (TSE:4502/NYSE:TAK) today announced changes to its executive leadership team to continue driving long-term growth in a highly competitive and dynamic global marketplace. The leadership changes, unless otherwise noted, will be effective at the start of Takeda’s fiscal year 2022 (April 1, 2022) and these executives will report to President and CEO Christophe Weber:

• Gabriele Ricci, who formerly served as Head of IT for the Plasma-Derived Therapies (PDT) Business Unit has been appointed Takeda’s Chief Data and Technology Officer, effective February 1, 2022. In this role, Gabriele will lead the critical transformation of the company’s Data, Digital and Technology division. Elevating and evolving the company’s existing IT function demonstrates the company’s commitment to creating an industry-leading data and technology approach to ultimately help better deliver life-transforming treatments to patients and society.
  
  
• Ramona Sequeira, who currently serves as President of the U.S. Business Unit and Global Portfolio Commercialization, has been appointed President, Global Portfolio Division. This newly created division in Takeda will bring together three global teams and three regional businesses to ensure the company can successfully bring new and existing global products to patients. Specifically, Ramona will have oversight over Global Medical, Global Product Launch Strategy, the Vaccine Business Unit as well as three regional business units including Europe and Canada, Growth and Emerging Markets and the China Business Unit.

• Julie Kim, who is currently President of the PDT Business Unit, has been appointed President of the U.S. Business Unit and U.S. country head. In this role, Julie will focus on continuing to grow Takeda’s business in the U.S., a key market for the company’s success.

• Giles Platford, who is currently President of the Europe and Canada Business Unit, has been appointed President of the PDT Business Unit, which will remain one of the most important growth drivers of revenue for Takeda over the coming years.
  
  

“My executive leadership team has been instrumental in helping to shape Takeda into a global, values-based biopharmaceutical company that delivers transformational medicine to patients around the world. Our strategy is working, and we continue to gain momentum – with competitive scale, a global footprint and a diverse pipeline with approximately 40 new molecular entities in clinical development,” said Christophe Weber, president and CEO, Takeda. “We are looking to the future, with clear goals in mind, including the opportunity to reinforce our global launch capabilities and harness data and digital to revolutionize the patient experience. This is the team that will help take us to the next level and ensure that we continue to grow and evolve.”

In addition, Takeda will expand the roles of other executive team members, including Lauren Duprey, Chief Human Resource Officer, to further focus on employee well-being; Takako Ohyabu, Chief Global Corporate Affairs and Sustainability Officer, to accelerate delivering against our purpose-led sustainability agenda; and Mwana Lugogo, Global Ethics and Compliance, to include data privacy. Takeda will also continue to have a focus on and commitment to its Oncology Business Unit and Japan Business Unit, along with its other critical functional areas such as Research and Development, Finance, Business Development, Human Resources, Quality, Ethics & Compliance, Legal, Global Corporate Affairs, Corporate Strategy and Manufacturing with executive leadership of these areas continuing to report to Mr. Weber.

 

About Takeda

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

Media Contacts

Japanese Media

Ryoko Matsumoto 
[email protected] 
+81 (0) 3-3278-3414

U.S. and International Media

Megan Ostrower
[email protected]
+1 772-559-4924

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.